All
|
92
|
71
|
77.2
| |
35
|
27
|
77.1
| |
57
|
44
|
77.2
| |
Type of condition
| | | |
0.996
| | | | | | | | |
Cancer
|
57
|
44
|
77.2
| | | | | | | | | |
Non-cancer
|
35
|
27
|
77.1
| | | | | | | | | |
Submission characteristics
|
Presence of RCTs
| | | |
0.083
| | | |
0.033
| | | |
0.727
|
No
|
22
|
14
|
63.6
| |
7
|
3
|
42.9
| |
15
|
11
|
73.3
| |
Yes
|
70
|
57
|
81.4
| |
28
|
24
|
85.7
| |
42
|
33
|
78.6
| |
Therapeutic class of drug
| | | |
0.714
| | | |
0.418
| |
NA
| | |
Alimentary tract & metabolism
|
10
|
9
|
90.0
| |
10
|
9
|
90.0
| | | | | |
Antineoplastic & immunomodulating
|
68
|
51
|
75.0
| |
11
|
7
|
63.6
| | | | | |
Others
|
14
|
11
|
78.6
| |
14
|
11
|
78.6
| | | | | |
Characteristics of disease
|
Prevalence
| | | |
1.000
| | | |
1.000
| | | |
1.000
|
Ultra- orphan
|
14
|
11
|
78.6
| |
8
|
6
|
75.0
| |
6
|
5
|
83.3
| |
Orphan
|
78
|
60
|
96.9
| |
27
|
21
|
77.8
| |
51
|
39
|
76.5
| |
Clinical need
| | | |
0.051
| | | |
0.419
| | | |
0.070
|
No/ not stated
|
28
|
18
|
64.3
| |
20
|
14
|
70.0
| |
8
|
4
|
50.0
| |
Yes
|
64
|
53
|
82.8
| |
15
|
13
|
86.7
| |
49
|
40
|
81.6
| |
Clinical safety/ efficacy
|
Safety issues
| | | |
0.021
| | | |
0.226
| | | |
0.102
|
Yes
|
33
|
21
|
63.6
| |
11
|
7
|
63.6
| |
22
|
14
|
63.6
| |
No
|
59
|
50
|
84.7
| |
24
|
20
|
83.3
| |
35
|
30
|
85.7
| |
Improvements in biomarker/surrogate outcomes
| | | |
0.316
| | | |
0.228
| | | |
0.006
|
No/ inconsistent/ not measured
|
27
|
19
|
70.4
| |
17
|
15
|
88.2
| |
10
|
4
|
40.0
| |
Yes
|
65
|
52
|
80.0
| |
18
|
12
|
66.7
| |
47
|
40
|
85.1
| |
Improvements in clinical outcomes
| | | |
0.005
| | | |
0.073
| | | |
0.084
|
No/ inconsistent/ not measured
|
66
|
46
|
69.7
| |
25
|
17
|
68.0
| |
41
|
29
|
70.7
| |
Yes
|
26
|
25
|
96.1
| |
10
|
10
|
100.0
| |
16
|
15
|
93.7
| |
Improvements in PRO
| | | |
0.010
| | | |
0.299
| | | |
0.042
|
No/ inconsistent/ not measured
|
67
|
47
|
70.1
| |
29
|
21
|
72.4
| |
38
|
26
|
68.4
| |
Yes
|
25
|
24
|
96.0
| |
6
|
6
|
100.0
| |
19
|
18
|
94.7
| |
Quality of evidence
|
Availability of comparative data
| | | |
0.427
| | | |
1.000
| | | |
0.510
|
No
|
33
|
27
|
81.8
| |
14
|
11
|
78.6
| |
19
|
16
|
84.2
| |
Yes
|
59
|
44
|
74.6
| |
21
|
16
|
76.2
| |
38
|
28
|
73.7
| |
Consistency between population in trials and indications
| | | |
0.130
| | | |
0.431
| | | |
0.345
|
No
|
48
|
34
|
70.8
| |
21
|
15
|
71.4
| |
27
|
19
|
70.4
| |
Yes
|
44
|
37
|
84.1
| |
14
|
12
|
85.7
| |
30
|
25
|
83.3
| |
Bias in outcome measures
| | | |
0.503
| | | |
0.216
| | | |
1.000
|
Yes
|
54
|
43
|
79.6
| |
12
|
11
|
91.7
| |
42
|
32
|
76.2
| |
No
|
38
|
28
|
73.7
| |
23
|
16
|
69.6
| |
15
|
12
|
80.0
| |
Long term data
| | | |
0.186
| | | |
0.390
| | | |
0.346
|
No
|
62
|
45
|
72.6
| |
25
|
18
|
72.0
| |
37
|
27
|
73.0
| |
Yes
|
30
|
26
|
86.7
| |
10
|
9
|
90.0
| |
20
|
17
|
85.0
| |
Other study design issues
| | | |
0.202
| | | |
1.000
| | | |
0.044
|
Yes
|
58
|
42
|
72.4
| |
19
|
15
|
78.9
| |
39
|
27
|
69.2
| |
No
|
34
|
29
|
85.3
| |
16
|
12
|
75.0
| |
18
|
17
|
94.4
| |
Cost/ cost-effectiveness
|
Daily treatment cost
| | | |
1.000
| | | |
0.298
| | | |
0.258
|
≤ 150
|
19
|
15
|
78.9
| |
13
|
12
|
92.3
| |
6
|
3
|
50.0
| |
150–500
|
52
|
40
|
76.9
| |
8
|
5
|
62.5
| |
44
|
35
|
79.6
| |
> 500
|
21
|
16
|
76.2
| |
14
|
10
|
71.4
| |
7
|
6
|
85.7
| |
ICER in $CDN/QALYs a
| | | |
0.647
| | | |
1.000
| | | |
0.194
|
≤ 100,000
|
12
|
11
|
91.7
| |
2
|
2
|
100.0
| |
10
|
9
|
90.0
| |
100,000-500,000
|
48
|
37
|
77.1
| |
7
|
6
|
85.7
| |
41
|
31
|
75.6
| |
> 500,000
|
16
|
13
|
81.2
| |
12
|
11
|
91.7
| |
4
|
2
|
50.0
| |